Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714433 | 0.92 | HTR2C (0.45) | HTR2CHTR2AMDM2CYP1A2CYP2C19 | |
| SCHEMBL6711135 | 0.86 | HTR2C (0.49) | HTR2CHTR2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6713804 | 0.85 | HTR2A (0.56) | HTR2CHTR2AHTR7HTR1ACYP1A2 | |
| SCHEMBL6714438 | 0.84 | HTR2C (0.52) | HTR2CHTR2ASOS1CYP1A2CYP2C19 | |
| SCHEMBL6719399 | 0.82 | HTR2C (0.52) | HTR2CHTR2AHTR7HTR1AHRH4 | |
| SCHEMBL6718623 | 0.78 | HTR2C (0.45) | HTR2CHTR2AHTR7MDM2CYP1A2 | |
| SCHEMBL6714458 | 0.78 | HTR2A (0.53) | HTR2CHTR2AHTR1AHRH4 | |
| SCHEMBL6711534 | 0.78 | HTR2A (0.47) | HTR2CHTR2AHTR7HTR1A | |
| SCHEMBL6719220 | 0.78 | HTR2A (0.47) | HTR2CHTR2AHTR7HTR1AHRH4 | |
| SCHEMBL6711075 | 0.77 | HTR2A (0.51) | HTR2CHTR2AHTR7HTR1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | ENNIS MICHAEL DALTON (US) | 2004-10-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HCRTR2, NR2C2, RCOR3 | HTR2C 553/4885HTR2A 1403/4885HTR7 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.